I view this as dispute has now moved to first quarter 2021. We had a shortfall with Dhsc invoices in 2020.Gm was pursuing this under his contractual rights. The DHSC then order PROmate first quarter stressed by GM in previous RNS . That to me was DHSc getting what they believed they were owed from 2020. The DHSc have oaid it but against the shortfall owing in 2020 so now the issue moves to 2021. At least we now have a number and it is most definitely factored into the price. Imo
Troublesome last time you offered to push me on a swing halfway up Hillseekers mountain it incurred the wrath of a MIA poster so I shall leave that one :)
If I was stuck up a mountain and had to survive you'd be one of my chosen ten on here VV , but I'd keep a very close eye on you in case you ate me !!! :)
13.02 haha Yep Mac economy versus science and I acknowledge the persuasive arguements for both whilst personally believing one could be to the ultimate detriment of the other longterm.
I only see this as 100% positive for us and the importance of Genomic surveillance globally and we know we are one of the chosen four. I think this will prove to be exremely lucrative to NCYT and like Bh2 I will now buy more but waiting on paperwork to be validated connected with US shares. Each to their own. K
Did you post that on the wrong board , can see you are getting a little frustrated over there. Sure we will all have good news soon , big boy pants on.